{"title":"Benzimidazole–dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA05462H","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA05462H\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,28889-28903<br /><b>DOI</b>: 10.1039/D4RA05462H, Paper</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Heba T. Abdel-Mohsen, Amira M. Nageeb<br />A series of new benzimidazole–dioxo(benzo)isoindoline conjugates were designed and synthesized as dual VEGFR-2 and FGFR-1 inhibitors. Compound <strong>8m</strong> demonstrated potent % inhibition of 80.69% and 76.83% on VEGFR-2 and FGFR-1 at 10 μM, respectively.<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"957c278e06c5cbfbabf39099ef5cf6a0c6b3722400373acda7191e0256ca2364","category":"Environment"}